Jacques Bouchy - Kineta Executive Development
| KA Stock | 0.48 0.04 7.69% |
Executive
Jacques Bouchy is Executive Development of Kineta Inc
| Age | 55 |
| Address | 219 Terry Ave. N, Seattle, WA, United States, 98109 |
| Phone | 206 378 0400 |
| Web | https://kinetabio.com |
Kineta Management Efficiency
The company has Return on Asset (ROA) of (1.1408) % which means that for every 100 dollars spent on asset, it generated a loss of $1.1408. This is way below average. Likewise, it shows a return on total equity (ROE) of (3.6901) %, which implies that it produced no returns to current stockholders. Kineta's management efficiency ratios could be used to measure how well Kineta manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -2.3. The current year's Return On Capital Employed is expected to grow to -4.65. At present, Kineta's Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 360.8 K, whereas Total Assets are forecasted to decline to about 9.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ana Rodriguez | Dyadic International | N/A | |
| MD MBA | Silo Pharma | 59 | |
| MD MBA | Molecular Partners AG | N/A | |
| MS MBA | Rezolute | 50 | |
| David Wambeke | DiaMedica Therapeutics | 40 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Ambarish Shah | DiaMedica Therapeutics | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Julie CCRP | DiaMedica Therapeutics | 50 | |
| Erin OBoyle | Rezolute | N/A | |
| Lorianne MD | DiaMedica Therapeutics | 63 | |
| Anne DVM | Molecular Partners AG | N/A | |
| Michael Covarrubias | Rezolute | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Gopal MBBS | Rezolute | N/A | |
Management Performance
| Return On Equity | -3.69 | ||||
| Return On Asset | -1.14 |
Kineta Inc Leadership Team
Elected by the shareholders, the Kineta's board of directors comprises two types of representatives: Kineta inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kineta. The board's role is to monitor Kineta's management team and ensure that shareholders' interests are well served. Kineta's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kineta's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Craig Philips, President Secretary | ||
| Gary Gentges, Executive Development | ||
| Jacques Bouchy, Executive Development | ||
| JD Esq, General Secretary | ||
| Thierry Guillaudeux, Chief Officer | ||
| Shawn Iadonato, Chair CEO | ||
| Keith Baker, Chief Officer |
Kineta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kineta a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.69 | ||||
| Return On Asset | -1.14 | ||||
| Current Valuation | 5.7 M | ||||
| Shares Outstanding | 12.26 M | ||||
| Shares Owned By Insiders | 34.89 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 28.54 K | ||||
| Price To Book | 9.65 X | ||||
| Price To Sales | 1.44 X | ||||
| Revenue | 5.44 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kineta Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kineta. If investors know Kineta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kineta listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Quarterly Revenue Growth (1.00) | Return On Assets (1.14) | Return On Equity (3.69) |
The market value of Kineta Inc is measured differently than its book value, which is the value of Kineta that is recorded on the company's balance sheet. Investors also form their own opinion of Kineta's value that differs from its market value or its book value, called intrinsic value, which is Kineta's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kineta's market value can be influenced by many factors that don't directly affect Kineta's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kineta's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kineta is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kineta's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.